National and Kapodistrian University of Athens
Μελέτη της διαγνωστικής αξίας των microRNAs στην προκαλούμενη από τη χημειοθεραπεία καρδιοτοξικότητα σε γυναίκες με καρκίνο του μαστού και υπερέκφραση του HER2 υποδοχέα
Abstract
dc:descriptionBackground: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients receive as adjuvant treatment chemotherapy and targeted therapy, including anthracyclines and trastuzumab. At the same time, they face an increased risk of cardiotoxicity, which may lead to long-term cardiovascular complications. Identifying biomarkers that predict cardiotoxicity is crucial for implementation of cardioprotective therapies. MicroRNAs have emerged as potential predictive factor of cardiotoxicity, due to their role in gene expression and cardiovascular homeostasis. Aim: This study aimed to evaluate the differential expression of circulating miRNAs in HER2-positive breast cancer patients undergoing anthracyclines and trastuzumab and explore their predictive value for anticancer therapy-induced cardiotoxicity. Methods: A total of 50 HER2-positive (group A), 23 HER2-negative breast cancer patients (group B) and 104 controls (group C) were included between May 2017 and August 2024. Groups A and B received epirubicin for 3 months after the baseline assessment, but only group A continued with trastuzumab for one year. Groups A and B were evaluated prospectively before (T0) and at 3 (T1), 6 (T2), 9, 12 and 15 (T3) months after the baseline assessment, while group C at T0, T1 and T3 respectively. Demographic, clinical and pathological data were collected. Left ventricle ejection fraction (LVEF) was performed at every visit, while blood samples for N-terminal prohormone of brain natriuretic peptide (NT-proBNP), high sensitivity troponin (hsTnI) and microRNAs, pulse wave velocity (PVW), augmentation index (AIx) and flow-mediated dilation (FMD) were assessed at T0, T1, T2 and T3. MicroRNAs’ expression profiling was performed using the miRCURY LNA miRNA PCR Panel, and differential expression was assessed using the 2−∆∆Ct method between two groups: cardiotoxicity and no cardiotoxicity. Additionally, five machine learning models (decision tree, random forest, SVM, GBM, kNN) were developed to classify cardiotoxicity based on miRNA expression levels. Results: 21.7% of breast cancer patients (A+B) developed symptomatic or asymptomatic cardiotoxicity. LVEF was statistically significantly reduced at 3 months and this reduction was preserved at 6 and 15 months of follow up (Τ0: 60.1 ± 4.4%, Τ1: 57.7 ± 5.0%, Τ2: 57.0 ± 4.8%, T3 57.1 ± 4.25%, p<0.001). PWV increase and FMD reduction were significant between T0 and T3 (PWV: p = 0.01 / FMD: p = 0.006), but not between T0 and T1 (PWV: p = 0.43 / FMD: p = 0.27). Additionally, treatment with trastuzumab did not change PWV and FMD (p-interaction= 0.74 and 0.91 respectively). Subjects with cardiotoxicity showed initially higher levels of ΝΤ-proBNP (122.0 ± 93.2pg/ml vs. 96.7 ± 71.3pg/ml, p=0.01), but not of hsTnI 3.43 ± 3.23pg/ml vs. 3.06 ± 2.06, p=0.26). Differential expression analysis of 84 microRNAs at T0 identified 24 microRNAs (hsa-miR-17-5p, hsa-miR-22-3p, hsa-miR-145-5p and hsa-miR-143-3p), which were significantly upregulated in the cardiotoxicity group and 21 (hsa-miR-155-5p, hsa-miR-124-3p και hsa-miR-133a-3p), which were respectively downregulated with at least a 2-fold difference between groups. The decision tree model used hsa-miR-17-5p as the primary decision node, classifying samples with an expression level of ≥27 ΔCT as non-cardiotoxic with 100% certainty. In cases where hsa-miR-17-5p was <27 ΔCT, hsa-miR-185-5p served as a secondary classifier, further distinguishing cardiotoxic and non-cardiotoxic cases with high accuracy. According to SVM, hsa-miR-143-3p, hsa-miR-133b, hsa-miR-145-5p and hsa-miR-185-5p were associated with cardiotoxicity. According to the random forest, hsa-miR-185-5p, hsa-miR-145-5p, hsa-miR-17-5p, and hsa-miR-133a-3p were associated with cardiotoxicity. Conclusion: This study underscores the potential of circulating miRNAs as biomarkers for predicting cardiotoxicity in HER2-positive breast cancer patients undergoing treatment with anthracyclines and trastuzumab. Machine learning models could provide valuable insights into miRNA-based risk stratification, paving the way for personalized cardiotoxicity monitoring and intervention strategies.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Anastasiou, Maria
- Αναστασίου, Μαρία
Subjects
dc:subject × 13Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/59963